Pharma Focus Asia

Merck and Samsung BioLogics Expand Strategic Alliance

Thursday, November 02, 2017

Merck , a leading science and technology company, today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance to manufacture biopharmaceutical products and the development of biological processes.

The alliance will accelerate the development of processes and the production of clinical material in small biotech start-ups focusing on the development of new drugs for which Samsung BioLogics acts as a contracted manufacturer. Under the terms of the agreement, Merck will provide Samsung BioLogics with technical support and process development in addition to its unique Mobius ® systems .

The new MoU is an extension of a MoU signed in 2014 that encompasses a long-term supply contract through which Merck would supply raw materials for the manufacture of biopharmaceuticals.

"Our collaboration with Samsung is further strengthened by this agreement," said Udit Batra , a member of Merck's board of directors and CEO of the Life Sciences division. "Merck's knowledge of process development, as well as its Mobius ® solution , the single-use bioprocessing portfolio, will enable patients to have faster access to innovations."

Merck is the leading solution provider for Samsung BioLogics 30KL and 152KL units in Korea, and has trained the Samsung BioLogics team to create a robust process for developing biological processes.

"This alliance will create synergy and maximize the potential of our technology," said Tae-Han Kim , president and CEO of Samsung BioLogics.

Merck's Mobius ® single use system portfolio provides more flexibility and continuity for this expansion, reducing the need to train operators. These are just a few of the many reasons why companies like Samsung BioLogics have pioneered the adoption of Merck technologies.

At Merck's M Lab ™ Collaboration Centers , customers work with the company's engineers and scientists in a shared exploratory environment to address customers' most complex biomanufacturing challenges and help them accelerate the development of new therapies. Merck has nine M Lab ™ Collaboration Centers worldwide, including one in the United States and one in Korea.

Merck is the leading provider of clinical stage manufacturing and process development solutions that are required for the production of biopharmaceutical drugs. The company is dedicated to providing superior bioreactor technologies to manufacturers, many of which are already collaborating with the company in this area in North America, Europe and Asia.

In the fast-growing biopharmaceutical market, manufacturers are turning to end-to-end solutions - from process development and scale change to the manufacturing of pre-clinical, clinical, and commercial products - as they look for ways to cut costs and increase quality and efficiency. At the same time, disposable, single-use systems have become more popular because they offer many advantages compared to conventional stainless steel systems, such as higher success rates per batch, less risk of cross-contamination, less need for water and waste of water, and a reduction in project duration and costs.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024